Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Solid Biosciences Inc
SLDB | US
7.31
USD-0.40
-5.19%
SLDB | US
About Solid Biosciences Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
13/03/2026
Close
7.31
Open
7.79
High
7.84
Low
7.16
Solid Biosciences Inc. a life science company engages in developing therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003 a next-generation gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne); AVB-202-TT a gene therapy program for the treatment of Friedreich's ataxia; AVB-401 a gene therapy program for the treatment of BAG3-mediated dilated cardiomyopathy; and other drugs for the treatment of undisclosed cardiac diseases. It also engages in developing platform technologies including dual gene expression a technology for packaging multiple transgenes into one vector as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown Massachusetts.
View LessSLDB | US
Risk
122.1
Sharpe
0.24
Luna's Score
42/100
Recommendation
Sell
Luna says (SLDB | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
150.3%1 month
122.1%3 months
91.8%6 months
89.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.32
Debt to equity
0.13
Debt to assets
0.11
Ent. to EBITDA
-3.69
Ent. to rev.
1.16
PEG
-
Other Fundamentals
EBITDA
-97.67M
MarketCap
282.13M
MarketCap(USD)
282.13M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-50.81
Short ratio
8.42
Short perc.
9.26
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.20
Range1M
3.49
Range3M
3.80
Volumes: Market Activity
Rel. volume
1.23
Price X volume
14.92M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.69 | - | Cheaper |
| Ent. to Revenue | 1.16 | - | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 1.32 | 13.15 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 91.81 | - | Riskier |
| Debt to Equity | 0.13 | -1.88 | Expensive |
| Debt to Assets | 0.11 | 0.48 | Cheaper |
| Market Cap | 282.13M | - | Emerging |
